Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Sandro M., Melchardt, Thomas, Egle, Alexander, Magnes, Teresa, Skrabs, Cathrin, Staber, Philipp, Simonitsch‐Klupp, Ingrid, Panny, Michael, Lehner, Barbara, Greil, Richard, Keil, Felix, Jäger, Ulrich, Sillaber, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://www.ncbi.nlm.nih.gov/pubmed/31838747
http://dx.doi.org/10.1111/ejh.13368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://www.ncbi.nlm.nih.gov/pubmed/31838747
http://dx.doi.org/10.1111/ejh.13368

Ejemplares similares